PMP22 and chronic inflammatory demyelinating polyradiculoneuropathy: IgG4 NF155+ CIDP presented the following clinical features that were significantly different compared with anti-NF155 antibody-negative (NF155−) CIDP (5): younger age at onset [average around 25 years old (range = 13–50) vs. 48 years old (range = 13–76)], higher frequencies of drop foot (69.2 vs. 31.7%), tremor (53.8 vs. 19.5%), and gait disturbance (100 vs. 73.2%).